Jacobs Levy Equity Management Inc. Sells 119,719 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Jacobs Levy Equity Management Inc. lessened its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 32.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 247,795 shares of the biotechnology company’s stock after selling 119,719 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.12% of BioCryst Pharmaceuticals worth $1,863,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock worth $164,616,000 after acquiring an additional 1,583,826 shares during the last quarter. Caligan Partners LP boosted its stake in BioCryst Pharmaceuticals by 16.0% during the 4th quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company’s stock worth $22,529,000 after acquiring an additional 412,347 shares during the last quarter. Northern Trust Corp boosted its stake in BioCryst Pharmaceuticals by 7.7% during the 4th quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company’s stock worth $15,077,000 after acquiring an additional 143,986 shares during the last quarter. Eversept Partners LP boosted its stake in BioCryst Pharmaceuticals by 269.9% during the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company’s stock worth $14,892,000 after acquiring an additional 1,444,907 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in BioCryst Pharmaceuticals by 4.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock worth $14,890,000 after acquiring an additional 91,998 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $10.21 on Friday. The company has a market capitalization of $2.14 billion, a P/E ratio of -16.74 and a beta of 1.08. The company’s 50 day moving average price is $8.06 and its two-hundred day moving average price is $7.95. BioCryst Pharmaceuticals, Inc. has a 52 week low of $5.92 and a 52 week high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. During the same quarter in the previous year, the business earned $0.28 EPS. The firm’s revenue was up 40.8% compared to the same quarter last year. Analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on BCRX shares. JPMorgan Chase & Co. lifted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 6th. StockNews.com lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. JMP Securities reissued a “market outperform” rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Wedbush began coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 target price on the stock. Finally, Needham & Company LLC raised their target price on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.56.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.